US Patent

US11191753 — Liquid pharmaceutical composition

Method of Use · Assigned to Ferring International Center SA · Expires 2034-06-23 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable liquid pharmaceutical composition containing sodium picosulfate, magnesium oxide, citric acid, and malic acid, and methods for making and using it.

USPTO Abstract

The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.

Drugs covered by this patent

Renacidin (CITRIC ACID) · Baxter

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3261`	—	Renacidin

Patent Metadata

Patent number: US11191753
Jurisdiction: US
Classification: Method of Use
Expires: 2034-06-23
Drug substance claim: No
Drug product claim: No
Assignee: Ferring International Center SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.